Monoclonal Antibody News and Research RSS Feed - Monoclonal Antibody News and Research

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Further Reading
Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA. [More]
Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades. [More]
Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen. [More]
Results of high-impact clinical trials could improve kidney-related medical care

Results of high-impact clinical trials could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL. [More]
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab). [More]
Photoimmunotherapy may be promising treatment option to combat cancer

Photoimmunotherapy may be promising treatment option to combat cancer

When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she's describing a Tom Clancy military espionage novel. [More]
Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers. [More]
New biologic medication shows promise in treating multi-drug resistant HIV patients

New biologic medication shows promise in treating multi-drug resistant HIV patients

A new biologic medication - the first for HIV - is showing promise in treating patients with multidrug resistance, according to phase 3 research being presented at IDWeek 2016. [More]
How could emerging technologies impact cancer care?

How could emerging technologies impact cancer care?

The major innovations in cancer diagnosis, therapy/palliative care and surgical intervention are too numerous to list here. But enormous strides have taken place in stem cell therapy, monoclonal antibody therapy and genetic screening. [More]
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. [More]
Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus. [More]
Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding. [More]

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. [More]
Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Scientists at Neurimmune today described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab. [More]
LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

As an arm of the innate immune system, white blood cells called neutrophils form the first line of defense against invading pathogens. [More]
Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. [More]
Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. [More]
New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

A new measurement standard developed by the National Institute of Standards of Technology has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer. [More]
New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. [More]
CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Cancer Treatment Centers of America at Western Regional Medical Center has dosed its first three patients as part of the launch of a Phase I clinical trial using a novel antibody to treat patients with advanced solid tumors. [More]
Advertisement
Advertisement